Evolus Debt to Equity Ratio 2016-2024 | EOLS
Current and historical debt to equity ratio values for Evolus (EOLS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Evolus debt/equity for the three months ending December 31, 2024 was 22.00.
| Evolus Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-12-31 | $0.23B | $0.01B | 41.12 |
| 2024-09-30 | $0.22B | $0.01B | 37.98 |
| 2024-06-30 | $0.21B | $0.02B | 11.10 |
| 2024-03-31 | $0.21B | $0.02B | 11.26 |
| 2023-12-31 | $0.21B | $-0.02B | -10.14 |
| 2023-09-30 | $0.19B | $-0.02B | -9.67 |
| 2023-06-30 | $0.18B | $-0.01B | -25.27 |
| 2023-03-31 | $0.15B | $0.01B | 22.06 |
| 2022-12-31 | $0.16B | $0.02B | 8.62 |
| 2022-09-30 | $0.16B | $0.03B | 5.60 |
| 2022-06-30 | $0.16B | $0.05B | 3.50 |
| 2022-03-31 | $0.15B | $0.07B | 2.28 |
| 2021-12-31 | $0.18B | $0.08B | 2.15 |
| 2021-09-30 | $0.12B | $0.10B | 1.21 |
| 2021-06-30 | $0.13B | $0.11B | 1.26 |
| 2021-03-31 | $0.13B | $0.02B | 5.75 |
| 2020-12-31 | $0.28B | $-0.07B | -3.87 |
| 2020-09-30 | $0.18B | $0.04B | 5.15 |
| 2020-06-30 | $0.15B | $0.04B | 3.46 |
| 2020-03-31 | $0.15B | $0.06B | 2.42 |
| 2019-12-31 | $0.16B | $0.08B | 2.03 |
| 2019-09-30 | $0.17B | $0.02B | 9.72 |
| 2019-06-30 | $0.16B | $0.04B | 3.92 |
| 2019-03-31 | $0.15B | $0.08B | 1.93 |
| 2018-12-31 | $0.09B | $0.08B | 1.04 |
| 2018-09-30 | $0.09B | $0.10B | 0.93 |
| 2018-06-30 | $0.08B | $0.04B | 2.21 |
| 2018-03-31 | $0.08B | $0.05B | 1.45 |
| 2017-12-31 | $0.23B | $-0.08B | -3.02 |
| 2017-09-30 | $0.00B | $0.00B | 0.00 |
| 2017-06-30 | $0.00B | $0.00B | 0.00 |
| 2017-03-31 | $0.00B | $0.00B | 0.00 |
| 2016-12-31 | $0.09B | $-0.01B | -11.92 |
| 2015-12-31 | $0.07B | $0.01B | 5.77 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.761B | $0.266B |
| Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. | |||